Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,591 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dextrose Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Terminated Not applicable Interventional Results available

Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors

NCT01243333
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
[F-18]fluorodeoxyglucose, [F-18]fluorothymidine, Positron Emission Tomography, Water O-15
Radiation · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 24, 2026, 5:26 AM EDT
Completed No phase listed Observational

Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

NCT00572858
View directory record Official record
Conditions
Estrogen Deficiency
Interventions
Blood test, Blood test, Ultrasound of neck arteries, Saliva test
Procedure · Genetic
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Up to 55 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
View directory record Official record
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

NCT02128932
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
136
States / cities
Birmingham, Alabama • Ozark, Alabama • Tuscumbia, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
View directory record Official record
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 24, 2026, 5:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome

NCT00690755
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 24, 2026, 5:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

NCT04500899
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Mydfrin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

NCT01572649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Chula Vista, California • Overland Park, Kansas • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Endothelial Function in Obese Adolescents

NCT01879033
View directory record Official record
Conditions
Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions
Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

NCT00607347
View directory record Official record
Conditions
Hypertension
Interventions
Glucose
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 24, 2026, 5:26 AM EDT
Terminated Not applicable Interventional

Effect of Meal Composition and Timing Modification on Glucose Metabolism, Body Temperature and Sleep

NCT05413928
View directory record Official record
Conditions
PreDiabetes, Type 2 Diabetes, Healthy
Interventions
Time Restrictive Eating- late, Time Restrictive Eating- early, Time Restrictive Eating- early with early caloric intake, Macronutrient-controlled meals
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Terminated Phase 2Phase 3 Interventional

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

NCT06820957
View directory record Official record
Conditions
CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Round Cell Sarcoma, Metastatic Undifferentiated Sarcoma, Not Otherwise Specified, Round Cell Sarcoma With EWSR1-non-ETS Fusion, Sarcoma With BCOR Genetic Alterations
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Fludeoxyglucose F-18, Ifosfamide, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Regorafenib, Surgical Procedure, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

NCT02561000
View directory record Official record
Conditions
Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions
PZ-128, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

NCT00872599
View directory record Official record
Conditions
Hypertension
Interventions
fenofibrate, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 24, 2026, 5:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

NCT06483945
View directory record Official record
Conditions
Diabetes
Interventions
Dexcom CGM G6/G6 Pro/G7
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
2 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Stockbridge, Georgia • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study

NCT00821067
View directory record Official record
Conditions
Fatigue
Interventions
D-ribose, Dextrose
Dietary Supplement
Lead sponsor
Bioenergy Life Science, Inc.
Industry
Eligibility
50 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 24, 2026, 5:26 AM EDT
Enrolling by invitation No phase listed Observational

Evaluation of the Typical Spinal Block During Cesarean Delivery

NCT06206044
View directory record Official record
Conditions
Cesarean Section, Anesthesia, Obstetric
Interventions
Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 55 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 24, 2026, 5:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform

NCT05121844
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
31,187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Enhancing Fitness in Older Pre-diabetic Veterans

NCT00594399
View directory record Official record
Conditions
Impaired Glucose Tolerance, Obesity, Diabetes
Interventions
Physical Activity Counseling
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 24, 2026, 5:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
View directory record Official record
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 5:26 AM EDT